MBX2319
MBX2319 is an AcrB inhibitor and antibiotic efficacy restorer that potently inhibits RND-type efflux pumps of Enterobacteriaceae species. MBX2319 increases antibacterial activity of fluoroquinolone and β-lactam antibiotics against Escherichia coli, restores antibiotic efficacy, and reduces antibiotic MIC against Gram-negative bacteria. MBX2319 has no inherent antibacterial activity against Escherichia coli and does not alter bacterial outer membrane permeability. MBX2319 can be used for the research of gram-negative bacterial infections and multidrug-resistant gram-negative bacterial infections.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 375836-83-2
- Formel: C23H27N3O2S
- Molecular Weight:409.54
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | CC50 |
> 100 μM
|
Cytotoxicity against human HeLa cells measured as concentration that decreases cell viability by 50% using standard cytotoxicity assay methods.
Cytotoxicity against human HeLa cells measured as concentration that decreases cell viability by 50% using standard cytotoxicity assay methods.
|
25818767 |
| HeLa | CC50 |
100 μM
Compound: MBX2319
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 25818767] |
In Vitro
MBX2319 (3.1 μM; 24 h) inhibits RND-type efflux pumps in wild-type Escherichia coli (AB1157), potentiating the activity of Levofloxacin (HY-B0330) and Piperacillin (HY-B1923) with an MPC4 of 3.1 μM for both antibiotics, while showing no inherent antibacterial activity at concentrations up to 100 μM[1].
MBX2319 (>100 μM) is non-cytotoxic to HeLa cells, with a CC50 greater than 100 μM[1].
MBX2319 (25 μM; 60 min) is completely unstable in pooled mouse and human liver microsomes, with 0% of the compound remaining after 60 minutes of incubation at 37 °C[1].
MBX2319 (3 μM; 10 min) exhibits low inhibition of CYP450 3A4, causing 12% inhibition at a concentration of 3 μM[1].
MBX2319 binds tightly to the hydrophobic trap near the DP-AP interface of the Escherichia coli AcrB B protomer with a calculated ΔGb of -12.5 kcal/mol, closing the upper DP crevice to block substrate binding and inhibit efflux pump function[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 375836-83-2
-
Molecular Weight 409.54
-
Formel C23H27N3O2S
-
SMILES
N#CC1=C(SCCC2=CC=CC=C2)N=C(N3CCOCC3)C4=C1CC(C)(C)OC4
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Nguyen ST, et al. Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors. Bioorganic & medicinal chemistry. 2015 May 01;23(9):2024-34. [Content Brief]
[2]. Vargiu AV, et al. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrobial agents and chemotherapy. 2014 Oct;58(10):6224-34. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
MBX2319 Related Classifications
HY-188076 Related Classifications
Powered by Bioz